STOCK TITAN

Kiora Pharmaceuticals, Inc. - KPRX STOCK NEWS

Welcome to our dedicated page for Kiora Pharmaceuticals news (Ticker: KPRX), a resource for investors and traders seeking the latest updates and insights on Kiora Pharmaceuticals stock.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) is a clinical-stage biotechnology company committed to the development and commercialization of innovative treatments for orphan retinal diseases. The company's lead product candidate, KIO-301, is aimed at treating inherited retinal diseases such as retinitis pigmentosa, choroideremia, and Stargardt disease. KIO-301 is a molecular photoswitch with the potential to restore vision in patients suffering from inherited and age-related retinal degeneration.

Kiora’s second key asset, KIO-104, is being developed to treat posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, with the promise of reducing retinal inflammation without the adverse effects associated with systemic anti-inflammatory drugs or chronic steroid use.

Most recently, Kiora announced its third quarter 2023 financial results and discussed the advancement of KIO-301 for other inherited retinal diseases. The ABACUS-1 study, a Phase 1b clinical trial of KIO-301, demonstrated safety and tolerability, along with significant improvements in visual field and functional vision. These promising results have paved the way for the company to initiate the ABACUS-2 trial, a Phase 2 study involving up to 20 patients with retinitis pigmentosa.

The company also entered into a strategic development and commercialization agreement with Théa Open Innovation (TOI), providing up to $285 million in potential milestone payments, alongside reimbursement of research and development expenses. This partnership will help Kiora accelerate the development and commercialization of KIO-301 globally, excluding Asia.

Moreover, Kiora announced a successful securities purchase agreement, raising up to $45 million to support its ongoing development activities. Recent strategic partnerships and financial maneuvers are expected to fund the company’s operations through 2026, offering a robust financial foundation for future growth.

Operating from Encinitas, California, Kiora continues to pioneer in the biotech space, aiming to bring transformative therapies to market for patients suffering from rare retinal diseases. The company remains focused on delivering innovative solutions that address significant unmet medical needs in ophthalmology.

Rhea-AI Summary
Results from ABACUS study of KIO-301 in patients with retinitis pigmentosa to be presented at AAO 2023 conference on Nov 4, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
conferences clinical trial
-
Rhea-AI Summary
Kiora Pharmaceuticals adjourns Special Meeting due to lack of quorum, seeks additional votes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
none
-
Rhea-AI Summary
Kiora Pharmaceuticals to host webinar on molecular photoswitches in retinal diseases, partnership with CRF
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
conferences
Rhea-AI Summary
Kiora Pharmaceuticals announces the granting of U.S. and European patents for ocular delivery of KIO-100 family of small molecules, extending market exclusivity. KIO-104 shows promising results in Phase 1b study for posterior non-infectious uveitis. Potential commercial position for KIO-104 as a safe and potent steroid-sparring approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.55%
Tags
none
-
Rhea-AI Summary
Kiora Pharmaceuticals partners with B2i Digital for investor engagement and awareness program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
-
Rhea-AI Summary
Kiora Pharmaceuticals focuses on rare retinal diseases in online presentation at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Kiora Pharmaceuticals reported positive preliminary data from the ABACUS Phase 1b clinical trial, supporting the advancement of KIO-301 in the treatment of Retinitis Pigmentosa. The company plans to expand clinical development to include Choroideremia and Stargardt's Disease. Kiora will shift resources to develop KIO-104 for Posterior Non-Infectious Uveitis. Financially, the company raised $6.3 million in funding and received $1.2 million in research tax incentives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
partnership
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.79%
Tags
none

FAQ

What does Kiora Pharmaceuticals specialize in?

Kiora Pharmaceuticals specializes in developing and commercializing treatments for orphan retinal diseases such as retinitis pigmentosa, choroideremia, and Stargardt disease.

What are Kiora's key product candidates?

Kiora’s key product candidates are KIO-301, a molecular photoswitch for inherited retinal diseases, and KIO-104, an immuno-modulatory inhibitor for treating posterior non-infectious uveitis.

What recent clinical trial results has Kiora announced?

Kiora announced positive results from the ABACUS-1 study, demonstrating that KIO-301 is safe and tolerable, with significant improvements in visual field and functional vision.

What partnerships has Kiora Pharmaceuticals formed recently?

Kiora has entered a strategic development and commercialization agreement with Théa Open Innovation (TOI), providing significant financial support and global development expertise.

How is Kiora Pharmaceuticals funded for its operations?

Kiora is funded through strategic partnerships, such as the one with TOI, and successful securities purchase agreements, providing a robust financial foundation expected to last through 2026.

What is the focus of Kiora’s KIO-104 product candidate?

KIO-104 focuses on treating posterior non-infectious uveitis and aims to reduce retinal inflammation without the side effects of systemic anti-inflammatory drugs or chronic steroids.

What are the latest financial results for Kiora Pharmaceuticals?

In the third quarter of 2023, Kiora reported net losses and increased R&D expenses due to clinical trials, with a strategic focus on advancing KIO-301 and KIO-104.

Where is Kiora Pharmaceuticals headquartered?

Kiora Pharmaceuticals is headquartered in Encinitas, California.

What is retinitis pigmentosa?

Retinitis pigmentosa is a hereditary degenerative disorder affecting the retina's photoreceptors, leading to progressive vision loss. There are currently no approved therapies.

How can investors stay updated on Kiora Pharmaceuticals?

Investors can stay updated by following Kiora’s news releases, SEC filings, and social media accounts or by subscribing to email alerts on the company’s website.

Kiora Pharmaceuticals, Inc.

Nasdaq:KPRX

KPRX Rankings

KPRX Stock Data

13.13M
2.97M
0.9%
49.25%
1.24%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
ENCINITAS